Pharma

Your Article Summary

See Latest Articles

Shire Completes Submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and Reports Positive Results for Remaining Two Phase III Trials
Shire, 09/02/09

Cambridge, Massachusetts, US – Shire plc, the global specialty biopharmaceutical company, reported that it has completed its submission of a New Drug Application for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration. The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09

A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

 See all of Drug Trials